An apparatus for assaying biofluid includes a receptacle for removably housing a set of cuvettes of a biofluid sample dispensing apparatus, each cuvette of the set of cuvettes containing an assay sample having a reagent and a sample of the biofluid; a receptacle sealing element disposed around the receptacle for providing sealing engagement between the receptacle and the biofluid sample dispensing apparatus for sealing the set of cuvettes within the receptacle; a vacuum source for evacuating the receptacle; and an automated assay system connected to the receptacle for performing an assay process on the assay samples in the set of cuvettes, while maintaining the set of cuvettes within the receptacle.

The invention relates to biosensors for detecting odorants, especially a biosensor that mimics odorant detection by a mammal, for example, humans, dogs or cats. The field of the invention also related to the standardization of odors for scent, smell and taste using the biosensor of the invention, and the discovery of agonists, antagonists, and mixtures of odorants for creating new odors, masking odors, enhancing odors, and designing odors.

The invention relates to biosensors for detecting odorants, especially a biosensor that mimics odorant detection by a mammal, for example, humans, dogs or cats. The field of the invention also related to the standardization of odors for scent, smell and taste using the biosensor of the invention, and the discovery of agonists, antagonists, and mixtures of odorants for creating new odors, masking odors, enhancing odors, and designing odors.

The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising an (i) MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.

The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising an (i) MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.

The present invention relates to a method for diagnosing and treating atherosclerosis by using nanovesicle targeting a site of change in blood flow, and more specifically, the present invention provides a stem cell-derived nanovesicle, which is an anti-atherosclerosis diagnosis and treatment platform using a peptide capable of targeting a disturbed blood flow, wherein the nanovesicle provides strong anti-inflammatory and pre-endothelial recovery effects similar to that of a mesenchymal stem cell, and thus it can be used as a new diagnosis and treatment agent capable of preventing the onset of atherosclerosis.

The present invention relates to a method for diagnosing and treating atherosclerosis by using nanovesicle targeting a site of change in blood flow, and more specifically, the present invention provides a stem cell-derived nanovesicle, which is an anti-atherosclerosis diagnosis and treatment platform using a peptide capable of targeting a disturbed blood flow, wherein the nanovesicle provides strong anti-inflammatory and pre-endothelial recovery effects similar to that of a mesenchymal stem cell, and thus it can be used as a new diagnosis and treatment agent capable of preventing the onset of atherosclerosis.

A system for assaying biofluid samples including an assay apparatus and a dispensing apparatus. The dispensing apparatus includes cuvettes that contain reagents and the biofluid samples to form assay samples, and the assay apparatus has a receptable for receiving and sealing the cuvettes inside. Once the cuvettes are sealed in the receptable, the assay apparatus performs assay processes on the assay samples in the cuvettes.

A system for assaying biofluid samples including an assay apparatus and a dispensing apparatus. The dispensing apparatus includes cuvettes that contain reagents and the biofluid samples to form assay samples, and the assay apparatus has a receptable for receiving and sealing the cuvettes inside. Once the cuvettes are sealed in the receptable, the assay apparatus performs assay processes on the assay samples in the cuvettes.

Described are methods, compositions, and devices for early detection and prevention of diseases, including cancer, infectious diseases, and autoimmune diseases, using broad-spectrum enrichment technology and single cell sequencing technology. An example method for detecting circulating tumor cells (CTCs) using platelet membrane-coated nanoparticles (PNPs) and single cell RNA sequencing (scRNA-seq) technology is also provided.